Biogenera Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
10
Biogenera General Information
Description
Developer of biotechnology pharmaceutical therapies intended to research and develop DNA-based medicines for the treatment of serious diseases. The company offers DNA-based biotechnological medicines, gene-specific molecules, MyGenera platform, drug development processes, and preclinical research activities, enabling pharmaceutical researchers and healthcare organizations access to tools for developing patient-specific treatments targeting mutated genes.
Contact Information
Website
www.biogenera.comCorporate Office
- Via dell'Artigianato 2
- Ozzano dell'Emilia
- 40064 Bologna
- Italy
Corporate Office
- Via dell'Artigianato 2
- Ozzano dell'Emilia
- 40064 Bologna
- Italy
Biogenera Timeline
Biogenera Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Accelerator/Incubator | 01-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 10. Equity Crowdfunding | 29-Jun-2024 | Completed | Pre-Clinical Trials | |||
| 9. Equity Crowdfunding | Completed | Pre-Clinical Trials | ||||
| 8. Later Stage VC (Series A) | 01-Oct-2021 | Completed | Pre-Clinical Trials | |||
| 7. Equity Crowdfunding | 25-Jun-2021 | Completed | Startup | |||
| 6. Reverse Merger | 16-Jul-2020 | Cancelled | Startup | |||
| 5. Equity Crowdfunding | 21-Oct-2018 | Completed | Startup | |||
| 4. Equity Crowdfunding | 03-Oct-2017 | Completed | Startup | |||
| 3. Seed Round | 24-Jun-2015 | $2.57M | $6.05M | Completed | Startup | |
| 2. Seed Round | 01-Jun-2013 | $1.5M | $3.48M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Biogenera Patents
Biogenera Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2013223694-A1 | Oligonucleotides for modulating gene expression and uses thereof | Active | 24-Feb-2012 | ||
| AU-2013223694-B2 | Oligonucleotides for modulating gene expression and uses thereof | Active | 24-Feb-2012 | ||
| AU-2018278972-A1 | Oligonucleotides for modulating gene expression and uses thereof | Inactive | 24-Feb-2012 | ||
| CA-2864060-A1 | Oligonucleotides for modulating gene expression and uses thereof | Active | 24-Feb-2012 | ||
| EP-2817407-A2 | Oligonucleotides for modulating gene expression and uses thereof | Active | 24-Feb-2012 | C12N15/1135 |
Biogenera Signals
Biogenera Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| INNOVIT (San Francisco) | Accelerator/Incubator | |||
| Investinit | Venture Capital | Minority | ||
| Sistema Investimenti | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| FocusFuturo | Venture Capital | Minority |
Biogenera FAQs
-
When was Biogenera founded?
Biogenera was founded in 2008.
-
Where is Biogenera headquartered?
Biogenera is headquartered in Bologna, Italy.
-
What is the size of Biogenera?
Biogenera has 10 total employees.
-
What industry is Biogenera in?
Biogenera’s primary industry is Drug Discovery.
-
Is Biogenera a private or public company?
Biogenera is a Private company.
-
What is Biogenera’s current revenue?
The current revenue for Biogenera is .
-
How much funding has Biogenera raised over time?
Biogenera has raised $15M.
-
Who are Biogenera’s investors?
INNOVIT (San Francisco), Investinit, Sistema Investimenti, , and FocusFuturo are 5 of 10 investors who have invested in Biogenera.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process